世界の結核菌膿瘍治療市場の規模、シェア、傾向分析レポート – 業界の概要と 2031 年までの予測

結核菌膿瘍治療市場分析

Mycobacterium abscessus 治療の市場は、この病原菌がもたらす課題と、これらの課題に対処するための研究開発の継続的な取り組みの両方を反映して、いくつかの要因によって形成されています。Mycobacterium abscessus 感染症は、他の非結核性抗酸菌 (NTM) に通常有効なものを含む多くの抗生物質に対する耐性と、治療と根絶をさらに複雑にするバイオフィルムを形成する能力で知られています。治療の状況は通常、マクロライド、アミノグリコシド、場合によってはベータラクタムなどの抗生物質の組み合わせを含む多剤アプローチを伴います。このレジメンは、厳格な薬剤感受性試験によって決定された特定の菌株の感受性プロファイルに合わせて調整され、これらの感染症の管理における個別化医療の重要性を強調しています。

結核菌膿瘍治療市場規模

世界の結核菌膿瘍治療市場規模は、2023年に4億9,198万米ドルと評価され、2024年から2031年の予測期間中に7.67%のCAGRで成長し、2031年には8億8,860万米ドルに達すると予測されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、データブリッジ市場調査がまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

レポートの範囲と市場セグメンテーション       

Mycobacterium Abscessus Treatment Market Definition

Mycobacterium abscessus is a species of rapidly growing, nontuberculous mycobacteria (NTM) that can cause infections in humans, particularly in individuals with compromised immune systems or underlying lung conditions such as cystic fibrosis. Treatment of Mycobacterium abscessus infections can be challenging due to the bacterium's inherent resistance to many antibiotics and its ability to form biofilms, which further complicates eradication.                                           

Mycobacterium Abscessus Treatment Market Dynamics

Drivers

• Increasing Incidence of Infections

The increasing incidence of Mycobacterium abscessus infections, particularly among immunocompromised individuals and those with respiratory conditions like cystic fibrosis, underscores the growing demand for effective treatments. As these infections become more prevalent, healthcare providers face heightened challenges in managing and treating patients, necessitating advancements in therapeutic options to address the diverse clinical presentations and antibiotic resistance profiles observed in Mycobacterium abscessus, driving the market growth.                       

• Antibiotic Resistance of Mycobacterium Abscessus    

The pervasive antibiotic resistance exhibited by Mycobacterium abscessus, including resistance to standard therapies used against nontuberculous mycobacteria (NTM), underscores the critical need for new treatment modalities and combination therapies. Current treatment regimens often involve multidrug approaches, yet the bacterium's ability to develop resistance mechanisms complicates therapeutic efficacy. Addressing antibiotic resistance through innovative drug development and precision medicine approaches remains pivotal in improving treatment outcomes, reducing the global burden of Mycobacterium abscessus infections, and driving market growth.

Opportunities

• Development of Novel Therapies

Pharmaceutical companies have significant opportunities to pioneer the development and commercialization of novel antibiotics, combination therapies, and alternative treatment strategies specifically targeting Mycobacterium abscessus infections. These advancements are crucial in overcoming existing antibiotic resistance challenges and enhancing therapeutic efficacy against this pathogen. By focusing on innovative research and clinical trials, companies can potentially introduce breakthrough treatments that offer improved outcomes and better patient management options.

• Advancements in Diagnostic Technologies

Ongoing advancements in diagnostic technologies, such as rapid molecular testing and point-of-care diagnostics, present promising opportunities to enhance early detection and treatment initiation for Mycobacterium abscessus infections. These technologies enable healthcare providers to swiftly identify the bacterium and determine its antibiotic susceptibility profile, facilitating timely treatment decisions and optimizing patient care outcomes. The integration of these advanced diagnostics into clinical practice holds the potential to streamline healthcare workflows and improve the overall management of Mycobacterium abscessus infections creating new opportunities for the market.

Restraints/Challenges

• Limited Treatment Options for Mycobacterium Abscessus

The limited efficacy of current antibiotics against resistant strains of Mycobacterium abscessus, compounded by challenges related to biofilm formation, restricts treatment options and compromises therapeutic outcomes. Healthcare providers often face difficulties in achieving complete eradication of the bacterium, leading to prolonged treatment durations and increased risks of treatment failure or relapse.  

• High Healthcare Costs

The high healthcare costs associated with managing Mycobacterium abscessus infections stem from the need for prolonged and complex treatment regimens, specialized care requirements, and the use of expensive antibiotics and diagnostic tools. These costs place significant financial burdens on healthcare systems and patients alike, underscoring the importance of developing cost-effective treatment strategies and optimizing healthcare resource utilization.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Mycobacterium Abscessus Treatment Market Scope

The market is segmented on the basis of drugs, bacteria type, indication, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

• Isoniazid
• Ethambutol
• Rifampin
• Clarithromycin
• Azithromycin
• Rifabutin
• Streptomycin
• Amikacin
• Others

Bacteria Type

• M. tuberculosis
• M. leprae
• Non-tuberculosis Mycobacteria
• Others

Indication

• Tuberculosis
• Leprosy
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare settings
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Mycobacterium Abscessus Treatment Market Regional Analysis

The market is analyzed and market size insights and trends are provided by country, drugs, bacteria type, indication, route of administration, end-users, and distribution channel as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to increasing prevalence of the disease in the region. Factors contributing to this growth include advanced healthcare infrastructure, high awareness among healthcare providers and patients, and substantial investments in research and development aimed at combating antibiotic resistance and improving treatment outcomes. 

Asia-Pacific is expected to witness significant growth during the forecast period due to proactive initiatives led by the World Health Organization (WHO) and various government awareness programs across the region. These efforts aim to raise awareness about NTM infections, including Mycobacterium abscessus, among healthcare professionals and the general population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Mycobacterium Abscessus Treatment Market Share

市場競争環境では、競合他社ごとの詳細が提供されます。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などが含まれます。提供される上記のデータ ポイントは、市場に関連する会社の焦点にのみ関連しています。

市場で活動している主要企業は次のとおりです。

• アストラゼネカ（英国）
• リリー（米国）
• F.ホフマン・ラ・ロシュ社（スイス）
• マイランNV（米国）
• テバ製薬工業株式会社（イスラエル）
• サノフィ（フランス）
• ノバルティスAG（スイス）
• サン・ファーマシューティカル・インダストリーズ（インド）
• オーロビンドファーマ（インド）
• ルピナス（インド）
• メルク社（米国）
• ファイザー社（米国）
• GSK plc（英国）
• ヒクマ・ファーマシューティカルズPLC（英国）
• シプラ社（インド）

マイコバクテリウム・アブセッサス治療市場の最新動向

• 2022年10月、ワシントンDCで開催されたASM Microbe 2022で、マイクロビオン社は、緑膿菌、黄色ブドウ球菌、大腸菌、マイコバクテリウム・アビウムなどの細菌のエネルギーに対するプラビビスマンの影響に関する有望な研究結果を発表しました。この化合物は、細菌の生体エネルギーとタンパク質合成を効果的に阻害することが示されました。
• 2022年9月、オックスフォード・イムノテックは、T-SPOT.TB検査のワークフローを合理化するために設計されたT-Cell Select試薬キットのFDA承認を取得しました。この世界的に規制されているELISPOT IGRA検査は、潜在性結核（TB）感染を検出し、認定された研究室での体外診断用に使用することを目的としています。

SKU-69220